Summit Therapeutics Inc.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company founded in 2003 and headquartered in Cambridge, Massachusetts. Originally focused on developing treatments for infectious diseases, the company underwent a strategic transformation in 2022 when it pivoted entirely to oncology. Summit acquired the rights to develop and commercialize ivonescimab, a promising cancer immunotherapy, through a landmark $500 million licensing agreement with Chinese biotech company Akeso. The company is now focused exclusively on advancing this bispecific antibody through late-stage clinical trials for various cancer indications, particularly non-small cell lung cancer.

Summit Therapeutics has undergone a dramatic strategic transformation over the past few years, evolving from an infectious disease-focused company to a pure-play oncology developer. The most significant pivot occurred in 2022 when Summit paid $500 million to license ivonescimab from Chinese partner Akeso, completely abandoning its previous focus on treatments for infections like Clostridioides difficile. Since the Akeso partnership, Summit has aggressively expanded its clinical development program for ivonescimab. The company has progressed from leveraging existing Chinese clinical data to conducting its own global Phase III trials, including the pivotal HARMONi trial for EGFR-mutated lung cancer patients and HARMONi-3 for first-line squamous non-small cell lung cancer. In 2024, Summit further expanded with the HARMONi-7 trial targeting PD-L1 high patients, demonstrating its commitment to exploring multiple patient populations. The company has also pursued strategic partnerships to accelerate development and expand ivonescimab's potential applications. Notable collaborations include a $15 million research alliance with MD Anderson Cancer Center and a clinical collaboration with Pfizer to evaluate ivonescimab in combination with antibody-drug conjugates (ADCs). These partnerships reflect Summit's strategy to explore combination therapies and expand beyond its initial lung cancer focus. Summit has been preparing for potential commercialization by hiring key personnel, including Chief Commercial Officer Robert LaCaze, and establishing manufacturing capabilities through contract manufacturers. The company has also secured important regulatory designations, including FDA Fast Track status for its EGFR-mutated lung cancer program, which could expedite the approval process. With over 30 investigator-sponsored trials approved globally and ivonescimab being studied across 17 different tumor types, Summit has positioned itself as a leader in bispecific antibody development, setting the stage for potential approvals and commercial launch in the coming years.